Comparison
Semax vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
80714-61-0
2179963-22-7
Molecular weight
813.92 g/mol
4727 g/mol
Half-life
0.3 h
168 h
Sequence
Met-Glu-His-Phe-Pro-Gly-Promodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2